CoChat

Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis

Open access
Gueorguieva, Ralitza, Chekroud, Adam M, Krystal, John H · 2017 · The Lancet Psychiatry

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Background Understanding patterns of relapse in patients who respond to antidepressant treatment can inform strategies for prevention of relapse. We aimed to identify distinct trajectories of depression severity, assess whether similar or different trajectory classes exist for patients who continued or discontinued active treatment, and test whether clinical predictors of trajectory class membership exist using pooled data from clinical trials.Methods We analysed individual patient data from four double-blind discontinuation clinical trials of duloxetine or fluoxetine versus placebo in major depression from before 2012 (n=1462). We modelled trajectories of relapse up to 26 weeks during double-blind treatment. Trajectories of depression severity, as measured by the Hamilton Depression Rating Scale score, were identified in the entire sample, and separately in groups in which antidepressants had been continued or discontinued, using growth mixture models. Predictors of trajectory class membership were assessed with weighted logistic regression.Findings We identified similar relapse trajectories and two trajectories of stable depression scores in the normal range on active medication and on placebo. Active treatment significantly lowered the odds of membership in the relapse trajectory (odds ratio 0·47, 95% CI 0·37-0·61), whereas female sex (1·56, 1·23-2·06), shorter length of time with clinical response by 1 week (1·10, 1·06-1·15), and higher Clinical Global Impression score at baseline (1·28, 1·01-1·62) increased the odds. Overall, the protective effect of antidepressant medication relative to placebo on the risk of being classified as a relapser was about 13% (33% vs 46%).Interpretation The existence of similar relapse trajectories on active medication and on placebo suggests that there is no specific relapse signature associated with antidepressant discontinuation. Furthermore, continued treatment offers only modest protection against relapse. These data highlight the need to incorporate treatment strategies that prevent relapse as part of the treatment of depression.Funding National Institutes of Health, the US Department of Veterans Affairs Alcohol Research Center, and National Center for Post-Traumatic Stress Disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(17)30038-x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A:Trajectories of HAMD scores in the active arms. B:Trajectories of HAMD scores in the placebo arms.
Figure 1 A:Trajectories of HAMD scores in the active arms. B:Trajectories of HAMD scores in the placebo arms.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 77

Metadata

Authors
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H.
Affiliations
  • Yale University (US)
  • Yale New Haven Hospital (US)
Corresponding author
Gueorguieva, Ralitza
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2017-03
Volume
4
Issue
3
Pages
230-237
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2586756570
Cited by
67
References
36
Citations by year
2026: 5 · 2025: 8 · 2024: 7 · 2023: 13 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 5 · 2018: 6 · 2017: 3
FWCI
0.73
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by)
  • PubMed Central (acceptedVersion, cc-by)
Funders
  • National Institutes of Health (grants K05AA14906 and 2P50AA012870)
  • National Center for Research Resources [NCRR] (grant UL1RR024139)
  • National Center for Advancing Translational Science [NCATS] (grant 5UL1TR000142)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
major depressive disorder, relapse, antidepressant discontinuation, duloxetine, fluoxetine, treatment continuation, depression severity, relapse prevention, predictors of relapse, individual patient data meta-analysis
MeSH terms
Duloxetine Hydrochloride, Adult, Antidepressive Agents, Major Depressive Disorder, Female, Fluoxetine, Humans, Male, Middle Aged, Patient Dropouts, Recurrence, Severity of Illness Index, Time Factors, Meta-Analysis as Topic, Placebo Effect, Treatment Outcome, Withholding Treatment, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. https://app.cochat.ai/papers/10.1016/s2215-0366(17)30038-x
The paper
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017). Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(17)30038-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.